Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy

Diagnostics: Liquid biopsy detects recurrence but lacks sensitivity A blood test can detect disease recurrence among women with triple-negative breast cancer (TNBC), but lacks sensitivity for distant relapse. A team led by Milan Radovich from Indiana University School of Medicine in Indianapolis, US...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yu-Hsiang Chen, Bradley A. Hancock, Jeffrey P. Solzak, Dumitru Brinza, Charles Scafe, Kathy D. Miller, Milan Radovich
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/644623fb59ef4bd68fdc77949dcce07a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:644623fb59ef4bd68fdc77949dcce07a
record_format	dspace
spelling	oai:doaj.org-article:644623fb59ef4bd68fdc77949dcce07a2021-12-02T16:19:49ZNext-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy10.1038/s41523-017-0028-42374-4677https://doaj.org/article/644623fb59ef4bd68fdc77949dcce07a2017-07-01T00:00:00Zhttps://doi.org/10.1038/s41523-017-0028-4https://doaj.org/toc/2374-4677Diagnostics: Liquid biopsy detects recurrence but lacks sensitivity A blood test can detect disease recurrence among women with triple-negative breast cancer (TNBC), but lacks sensitivity for distant relapse. A team led by Milan Radovich from Indiana University School of Medicine in Indianapolis, USA, analyzed tumor and blood plasma samples from 38 patients with TNBC who underwent neoadjuvant chemotherapy to see whether they could find evidence of mutated tumor DNA circulating in the blood after surgery that might predict cancer relapse. This kind of “liquid biopsy” has shown promise for patients with metastatic disease, but it has been tested less extensively in people with earlier-stage disease. The researchers’ blood test picked up tumor DNA in four patients after surgery, all of whom experienced disease recurrence. However, it missed nine other cases of relapse—indicating that the test has high specificity, but only moderate sensitivity.Yu-Hsiang ChenBradley A. HancockJeffrey P. SolzakDumitru BrinzaCharles ScafeKathy D. MillerMilan RadovichNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Breast Cancer, Vol 3, Iss 1, Pp 1-6 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Yu-Hsiang Chen Bradley A. Hancock Jeffrey P. Solzak Dumitru Brinza Charles Scafe Kathy D. Miller Milan Radovich Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy
description	Diagnostics: Liquid biopsy detects recurrence but lacks sensitivity A blood test can detect disease recurrence among women with triple-negative breast cancer (TNBC), but lacks sensitivity for distant relapse. A team led by Milan Radovich from Indiana University School of Medicine in Indianapolis, USA, analyzed tumor and blood plasma samples from 38 patients with TNBC who underwent neoadjuvant chemotherapy to see whether they could find evidence of mutated tumor DNA circulating in the blood after surgery that might predict cancer relapse. This kind of “liquid biopsy” has shown promise for patients with metastatic disease, but it has been tested less extensively in people with earlier-stage disease. The researchers’ blood test picked up tumor DNA in four patients after surgery, all of whom experienced disease recurrence. However, it missed nine other cases of relapse—indicating that the test has high specificity, but only moderate sensitivity.
format	article
author	Yu-Hsiang Chen Bradley A. Hancock Jeffrey P. Solzak Dumitru Brinza Charles Scafe Kathy D. Miller Milan Radovich
author_facet	Yu-Hsiang Chen Bradley A. Hancock Jeffrey P. Solzak Dumitru Brinza Charles Scafe Kathy D. Miller Milan Radovich
author_sort	Yu-Hsiang Chen
title	Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy
title_short	Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy
title_full	Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy
title_fullStr	Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy
title_full_unstemmed	Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy
title_sort	next-generation sequencing of circulating tumor dna to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/644623fb59ef4bd68fdc77949dcce07a
work_keys_str_mv	AT yuhsiangchen nextgenerationsequencingofcirculatingtumordnatopredictrecurrenceintriplenegativebreastcancerpatientswithresidualdiseaseafterneoadjuvantchemotherapy AT bradleyahancock nextgenerationsequencingofcirculatingtumordnatopredictrecurrenceintriplenegativebreastcancerpatientswithresidualdiseaseafterneoadjuvantchemotherapy AT jeffreypsolzak nextgenerationsequencingofcirculatingtumordnatopredictrecurrenceintriplenegativebreastcancerpatientswithresidualdiseaseafterneoadjuvantchemotherapy AT dumitrubrinza nextgenerationsequencingofcirculatingtumordnatopredictrecurrenceintriplenegativebreastcancerpatientswithresidualdiseaseafterneoadjuvantchemotherapy AT charlesscafe nextgenerationsequencingofcirculatingtumordnatopredictrecurrenceintriplenegativebreastcancerpatientswithresidualdiseaseafterneoadjuvantchemotherapy AT kathydmiller nextgenerationsequencingofcirculatingtumordnatopredictrecurrenceintriplenegativebreastcancerpatientswithresidualdiseaseafterneoadjuvantchemotherapy AT milanradovich nextgenerationsequencingofcirculatingtumordnatopredictrecurrenceintriplenegativebreastcancerpatientswithresidualdiseaseafterneoadjuvantchemotherapy
_version_	1718384170645848064

Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy

Ejemplares similares